Anemia continues to be an extremely common problem encountered in hematology clinical practice. Anemia is not a diagnosis by itself but is a sign associated with a broad range of clinical conditions. Diagnostic algorithms and treatment approaches to anemia are evolving as new data emerge.
Dr. Robert Means will discuss diagnosis of pure red cell aplasia (PRCA), clinical outcomes, and management of patients with PRCA and related conditions.
Dr. Michael Auerbach will review contemporary diagnosis and therapy of iron deficiency anemia, including emerging data supporting benefit of parenteral iron salts in pregnancy, cancer-associated anemia, idiopathic iron deficiency anemia and other conditions.
Dr. David Steensma will describe evaluation of patients with unexplained anemia in the era of molecular testing. He will review the entities clonal hematopoiesis of indeterminate potential (CHIP), idiopathic cytopenias of undetermined significance (ICUS), clonal cytopenias of undetermined significance (CCUS), and their distinction from hematological neoplasms.
Correction: On slide 16 of the presentation, the quote from Kidney International should be attributed to UpToDate, the American Journal of Hematology, and the European Medicines Agency. The correct quote from Kidney International reads as follows: “There is no physiological basis to recommend that patients should be observed for 30 minutes after an infusion of iron is completed, since i.v. iron delivery should not be associated with a severe delayed reaction (as is observed with subcutaneous antigen presentation in vaccination or allergen immune therapy).” We apologize for the error.